Initial characterization of an 18 F-labeled myocardial perfusion tracer

Marc C. Huisman, Takahiro Higuchi, Sybille Reder, Stephan G. Nekolla, Thorsten Poethko, Hans J̈urgen Wester, Sibylle I. Ziegler, David S. Casebier, Simon P. Robinson, Markus Schwaiger

Research output: Contribution to journalArticle

113 Citations (Scopus)

Abstract

PET allows for quantitative, regional myocardial perfusion imaging. The short half-lives of the perfusion tracers currently in use limit their clinical applicability. Here, the biodistribution and imaging quality of a new 18 F-labeled myocardial perfusion agent ( 18 F-BMS-747158-02) in an animal model are described. Methods: The biodistribution of 18 F-BMS-747158-02 was determined at 10 and 60 min after injection. The first-pass extraction fraction of the tracer was measured in isolated rat hearts perfused with the Langendorff method. Small-animal PET imaging was used to study tracer retention. Results: The biodistribution at 10 min after injection demonstrated high myocardial uptake (3.1 percentage injected dose per gram [%ID/g]) accompanied by little activity in the lungs (0.3 %ID/g) and liver (1.0 %ID/g). The tracer showed a high and flow-independent myocardial first-pass extraction fraction, averaging 0.94 (SD = 0.04). PET imaging provided excellent delineation of myocardial structures. The heart-to-lung activity ratio increased from 4.7 to 10.2 between 1 and 15 min after tracer injection (at rest). Adenosine infusion (140 μg/ kg/min) led to a significant increase in myocardial tracer retention (from 1.68 [SD = 0.23]) s -1 to 3.21 [SD = 0.92] s -1 ; P = 0.03). Conclusion: The observation of a high and flow-independent first-pass extraction fraction promises linearity between tracer uptake and myocardial blood flow. Sustained myocardial tracer uptake, combined with high image contrast, will allow for imaging protocols with tracer injection at peak exercise followed by delayed imaging. Thus, 18 F-BMS-747158-02 is a promising new tracer for the quantitative imaging of myocardial perfusion and can be distributed to imaging laboratories without a cyclotron.

Original languageEnglish
Pages (from-to)630-636
Number of pages7
JournalJournal of Nuclear Medicine
Volume49
Issue number4
DOIs
Publication statusPublished - Apr 1 2008
Externally publishedYes

Fingerprint

Perfusion
Injections
Myocardial Perfusion Imaging
Cyclotrons
Lung
Adenosine
Animal Models
Observation
Liver
BMS 747158-02

Keywords

  • Imaging
  • Myocardial perfusion
  • PET

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Huisman, M. C., Higuchi, T., Reder, S., Nekolla, S. G., Poethko, T., Wester, H. J., ... Schwaiger, M. (2008). Initial characterization of an 18 F-labeled myocardial perfusion tracer Journal of Nuclear Medicine, 49(4), 630-636. https://doi.org/10.2967/jnumed.107.044727

Initial characterization of an 18 F-labeled myocardial perfusion tracer . / Huisman, Marc C.; Higuchi, Takahiro; Reder, Sybille; Nekolla, Stephan G.; Poethko, Thorsten; Wester, Hans J̈urgen; Ziegler, Sibylle I.; Casebier, David S.; Robinson, Simon P.; Schwaiger, Markus.

In: Journal of Nuclear Medicine, Vol. 49, No. 4, 01.04.2008, p. 630-636.

Research output: Contribution to journalArticle

Huisman, MC, Higuchi, T, Reder, S, Nekolla, SG, Poethko, T, Wester, HJ, Ziegler, SI, Casebier, DS, Robinson, SP & Schwaiger, M 2008, ' Initial characterization of an 18 F-labeled myocardial perfusion tracer ', Journal of Nuclear Medicine, vol. 49, no. 4, pp. 630-636. https://doi.org/10.2967/jnumed.107.044727
Huisman, Marc C. ; Higuchi, Takahiro ; Reder, Sybille ; Nekolla, Stephan G. ; Poethko, Thorsten ; Wester, Hans J̈urgen ; Ziegler, Sibylle I. ; Casebier, David S. ; Robinson, Simon P. ; Schwaiger, Markus. / Initial characterization of an 18 F-labeled myocardial perfusion tracer In: Journal of Nuclear Medicine. 2008 ; Vol. 49, No. 4. pp. 630-636.
@article{0dc71ee9377b4b7b91926c4f080ad0f8,
title = "Initial characterization of an 18 F-labeled myocardial perfusion tracer",
abstract = "PET allows for quantitative, regional myocardial perfusion imaging. The short half-lives of the perfusion tracers currently in use limit their clinical applicability. Here, the biodistribution and imaging quality of a new 18 F-labeled myocardial perfusion agent ( 18 F-BMS-747158-02) in an animal model are described. Methods: The biodistribution of 18 F-BMS-747158-02 was determined at 10 and 60 min after injection. The first-pass extraction fraction of the tracer was measured in isolated rat hearts perfused with the Langendorff method. Small-animal PET imaging was used to study tracer retention. Results: The biodistribution at 10 min after injection demonstrated high myocardial uptake (3.1 percentage injected dose per gram [{\%}ID/g]) accompanied by little activity in the lungs (0.3 {\%}ID/g) and liver (1.0 {\%}ID/g). The tracer showed a high and flow-independent myocardial first-pass extraction fraction, averaging 0.94 (SD = 0.04). PET imaging provided excellent delineation of myocardial structures. The heart-to-lung activity ratio increased from 4.7 to 10.2 between 1 and 15 min after tracer injection (at rest). Adenosine infusion (140 μg/ kg/min) led to a significant increase in myocardial tracer retention (from 1.68 [SD = 0.23]) s -1 to 3.21 [SD = 0.92] s -1 ; P = 0.03). Conclusion: The observation of a high and flow-independent first-pass extraction fraction promises linearity between tracer uptake and myocardial blood flow. Sustained myocardial tracer uptake, combined with high image contrast, will allow for imaging protocols with tracer injection at peak exercise followed by delayed imaging. Thus, 18 F-BMS-747158-02 is a promising new tracer for the quantitative imaging of myocardial perfusion and can be distributed to imaging laboratories without a cyclotron.",
keywords = "Imaging, Myocardial perfusion, PET",
author = "Huisman, {Marc C.} and Takahiro Higuchi and Sybille Reder and Nekolla, {Stephan G.} and Thorsten Poethko and Wester, {Hans J̈urgen} and Ziegler, {Sibylle I.} and Casebier, {David S.} and Robinson, {Simon P.} and Markus Schwaiger",
year = "2008",
month = "4",
day = "1",
doi = "10.2967/jnumed.107.044727",
language = "English",
volume = "49",
pages = "630--636",
journal = "Journal of Nuclear Medicine",
issn = "0161-5505",
publisher = "Society of Nuclear Medicine Inc.",
number = "4",

}

TY - JOUR

T1 - Initial characterization of an 18 F-labeled myocardial perfusion tracer

AU - Huisman, Marc C.

AU - Higuchi, Takahiro

AU - Reder, Sybille

AU - Nekolla, Stephan G.

AU - Poethko, Thorsten

AU - Wester, Hans J̈urgen

AU - Ziegler, Sibylle I.

AU - Casebier, David S.

AU - Robinson, Simon P.

AU - Schwaiger, Markus

PY - 2008/4/1

Y1 - 2008/4/1

N2 - PET allows for quantitative, regional myocardial perfusion imaging. The short half-lives of the perfusion tracers currently in use limit their clinical applicability. Here, the biodistribution and imaging quality of a new 18 F-labeled myocardial perfusion agent ( 18 F-BMS-747158-02) in an animal model are described. Methods: The biodistribution of 18 F-BMS-747158-02 was determined at 10 and 60 min after injection. The first-pass extraction fraction of the tracer was measured in isolated rat hearts perfused with the Langendorff method. Small-animal PET imaging was used to study tracer retention. Results: The biodistribution at 10 min after injection demonstrated high myocardial uptake (3.1 percentage injected dose per gram [%ID/g]) accompanied by little activity in the lungs (0.3 %ID/g) and liver (1.0 %ID/g). The tracer showed a high and flow-independent myocardial first-pass extraction fraction, averaging 0.94 (SD = 0.04). PET imaging provided excellent delineation of myocardial structures. The heart-to-lung activity ratio increased from 4.7 to 10.2 between 1 and 15 min after tracer injection (at rest). Adenosine infusion (140 μg/ kg/min) led to a significant increase in myocardial tracer retention (from 1.68 [SD = 0.23]) s -1 to 3.21 [SD = 0.92] s -1 ; P = 0.03). Conclusion: The observation of a high and flow-independent first-pass extraction fraction promises linearity between tracer uptake and myocardial blood flow. Sustained myocardial tracer uptake, combined with high image contrast, will allow for imaging protocols with tracer injection at peak exercise followed by delayed imaging. Thus, 18 F-BMS-747158-02 is a promising new tracer for the quantitative imaging of myocardial perfusion and can be distributed to imaging laboratories without a cyclotron.

AB - PET allows for quantitative, regional myocardial perfusion imaging. The short half-lives of the perfusion tracers currently in use limit their clinical applicability. Here, the biodistribution and imaging quality of a new 18 F-labeled myocardial perfusion agent ( 18 F-BMS-747158-02) in an animal model are described. Methods: The biodistribution of 18 F-BMS-747158-02 was determined at 10 and 60 min after injection. The first-pass extraction fraction of the tracer was measured in isolated rat hearts perfused with the Langendorff method. Small-animal PET imaging was used to study tracer retention. Results: The biodistribution at 10 min after injection demonstrated high myocardial uptake (3.1 percentage injected dose per gram [%ID/g]) accompanied by little activity in the lungs (0.3 %ID/g) and liver (1.0 %ID/g). The tracer showed a high and flow-independent myocardial first-pass extraction fraction, averaging 0.94 (SD = 0.04). PET imaging provided excellent delineation of myocardial structures. The heart-to-lung activity ratio increased from 4.7 to 10.2 between 1 and 15 min after tracer injection (at rest). Adenosine infusion (140 μg/ kg/min) led to a significant increase in myocardial tracer retention (from 1.68 [SD = 0.23]) s -1 to 3.21 [SD = 0.92] s -1 ; P = 0.03). Conclusion: The observation of a high and flow-independent first-pass extraction fraction promises linearity between tracer uptake and myocardial blood flow. Sustained myocardial tracer uptake, combined with high image contrast, will allow for imaging protocols with tracer injection at peak exercise followed by delayed imaging. Thus, 18 F-BMS-747158-02 is a promising new tracer for the quantitative imaging of myocardial perfusion and can be distributed to imaging laboratories without a cyclotron.

KW - Imaging

KW - Myocardial perfusion

KW - PET

UR - http://www.scopus.com/inward/record.url?scp=42049114255&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=42049114255&partnerID=8YFLogxK

U2 - 10.2967/jnumed.107.044727

DO - 10.2967/jnumed.107.044727

M3 - Article

C2 - 18344426

AN - SCOPUS:42049114255

VL - 49

SP - 630

EP - 636

JO - Journal of Nuclear Medicine

JF - Journal of Nuclear Medicine

SN - 0161-5505

IS - 4

ER -